MENU
Home
Add Document
Sign In
Create An Account
PDF Reader
Full Text
The New England Journal of Medicine Downloaded from nejm.org at NYU WASHINGTON SQUARE CAMPUS on June 5, 2015. For personal use only. No other uses without permission. Copyright © 1992 Massachusetts Medical Society. All rights reserved.
The New England Journal of Medicine Downloaded from nejm.org at NYU WASHINGTON SQUARE CAMPUS on June 5, 2015. For personal use only. No other uses without permission. Copyright © 1992 Massachusetts Medical Society. All rights reserved.
Suggest Documents
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2.
Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.
Effect of a recombinant HIV gp160 vaccine on monokine production.
Pneumococcal vaccination in people living with HIV.
Artificial viral envelopes containing recombinant human immunodeficiency virus (HIV) gp160.
Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
Convergent evolution in the homology between HIV gp160 and HLA class II molecules.
gp160 of HIV-I synthesized by persistently infected Molt-3 cells is terminally glycosylated: evidence that cleavage of gp160 occurs subsequent to oligosaccharide processing.
Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
Properties of HIV membrane reconstituted from its recombinant gp160 envelope glycoprotein.
HIV false positivity after hepatitis B vaccination.
II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.
Developments in HIV-1 immunotherapy and therapeutic vaccination.
BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial.
Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.
Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection.
Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States.
Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.
Vaccination with gp160 in HIV.
The New England Journal of Medicine Downloaded from nejm.org at NYU WASHINGTON SQUARE CAMPUS on June 5, 2015. For personal use only. No other uses wit...
434KB Sizes
0 Downloads
0 Views
Download PDF
Recommend Documents
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2.
Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.
Effect of a recombinant HIV gp160 vaccine on monokine production.
Pneumococcal vaccination in people living with HIV.
Artificial viral envelopes containing recombinant human immunodeficiency virus (HIV) gp160.
Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
Convergent evolution in the homology between HIV gp160 and HLA class II molecules.
gp160 of HIV-I synthesized by persistently infected Molt-3 cells is terminally glycosylated: evidence that cleavage of gp160 occurs subsequent to oligosaccharide processing.
Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.
×
Sign In
Login with Facebook
Don't have an account?
Forgot Password?
×
Sign Up
By clicking register, I agree to your terms